510(K) CLEARANCES 84 ▲14RECALLS POSTED 39 ▲27CLASS I 6 ▲2PMA DECISIONS 47 ▲11WEEK ENDING / FDA DATA AS OF
Medical Device
ManufacturingTHE TRADE PAPER OF THE FACTORY FLOOR
SUBSCRIBE / SIGN IN
K032254Substantially Equivalent

Ibl C1q-Cic Cia Test

Ibl GmbH, East Stroudsburg PA / Traditional, Substantially Equivalent
FDA source (opens on fda.gov)

K032254 is the FDA 510(k) clearance record for IBL C1Q-CIC CIA TEST, a class II device, cleared for Ibl GmbH on under FDA product code DAK (Complement C1q, Antigen, Antiserum, Control). FDA records list 6 510(k) clearances for Ibl GmbH, from to . As of , FDA records show no recalls naming K032254.

Clearance record

Decision date
Received
(38 days to decision)
Product code
DAK Complement C1q, Antigen, Antiserum, Control
Regulation
21 CFR 866.5240
Device class
Class II
Review panel
Immunology
Applicant
Ibl GmbH 150 Cherry Ln. Rd., East Stroudsburg PA
510(k) summary
Statement
Third party review
No

Clearances, product code DAK

Trailing 12 months

FDA records hold no clearances under product code DAK in the trailing twelve months.

FDA records show no clearances under product code DAK in the twelve months to October 2026.
Show the numbers
Monthly 510(k) clearances under FDA product code DAK, trailing twelve months
MonthClearances
November 20250
December 20250
January 20260
February 20260
March 20260
April 20260
May 20260
June 20260
July 20260
August 20260
September 20260
October 20260